Clinical activity and effectiveness were defined in terms of partial Mayo score (PMS). Included were 113 UC patients who were exposed to tofacitinib for a median of 44 weeks. After 8 weeks, response and remission rates were 60% and 31%, respectively; these rates were still similar at week 16 (see Figure). Higher PMS at week 4 (OR 0.2; 95% CI 0.1–0.4) was associated with a reduced odds of achieving remission after 8 weeks. Higher PMS at week 4 (OR 0.5; 95% CI 0.3–0.7) and higher PMS at week 8 (OR 0.2; 95% CI 0.1–0.5) were associated with a lower chance of remission after 16 weeks. Of patients not in remission at week 4 and week 8, 20% and 12% achieved remission after 16 weeks. Noteworthy, 65% of patients in remission at week 8 relapsed within the next year.
Figure. Short-term effectiveness of tofacitinib in ulcerative colitis (last-observation-carried-forward method) [1]

Primary failure was the main reason for a total of 45 patients (40%) to discontinue tofacitinib over time. Only PMS at week 8 was associated with discontinuation (HR 1.5; 95% CI 1.3–1.6). Eighteen patients had adverse events, of which 4 were hypercholesterolaemia. No thromboembolic events were reported.
Early ‘real-world’ experience with tofacitinib in 4 UK tertiary centres resulted in similar efficacy and safety outcomes as had been reported in the pivotal OCTAVE clinical trials [2]. Response and remission rates were 73% (81/111) and 56% (62/111) respectively at week 8, and 48% (39/82) and 39% (32/82) respectively at week 26. Steroid-free remission was reached by 47% (52/111) and 37% (30/82) at week 8 and 26. There were 6 serious infections.
- Chaparro M, et al. ECCO-IBD 2020, OP29.
- Chee D, et al. ECCO-IBD 2020, DOP69.
Posted on
Previous Article
« Ustekinumab in CD: a T2T trial Next Article
Infliximab discontinuation increases relapse risk »
« Ustekinumab in CD: a T2T trial Next Article
Infliximab discontinuation increases relapse risk »
Table of Contents: ECCO 2020
Featured articles
Gut Microbiome as Treatment Target
Response to faecal microbiota transplantation in UC
Bioactives produced by gut bacteria to modulate immune response
Big Data Analysis
Multi-omics help describe CD phenotypes
The positive impact of genetic data on drug development
Experimental Therapies: Study Results
AMT-101: an oral human IL-10 fusion protein
Phase 2 results of first-in-class TL1A inhibitor
Open-label extension study of risankizumab: final results
Clinical remission after dose escalation of upadacitinib
Short- and Long-Term Treatment Results
Infliximab discontinuation increases relapse risk
Tofacitinib ‘real-world’ effectiveness in active UC
Subcutaneous ustekinumab as maintenance therapy in UC
Subcutaneous vedolizumab maintenance therapy in CD
Vedolizumab treatment persistence and safety
Specific Therapeutic Strategies
Impact of strategies on intestinal resection rate
Early ileocaecal resection in CD patients failing conventional treatment
Biologics before surgery in IBD do not elevate infection risk
Top-down infliximab superior to step-up in children with CD
High versus standard adalimumab in active UC
Head-to-Head Comparison of Treatments
Vedolizumab and anti-TNF therapies: a real-world comparison
Cancer Risk
Increased risk of small bowel cancer in IBD
Increased incidence of colorectal cancer and death in CD
Risk of rectal, anal cancer increased in perianal CD
Glyco-fingerprint as risk factor of UC-associated cancer
Miscellaneous Topics
Resolution of mucosal inflammation has dramatic effect
PICaSSO validated in real-life study
Re-inducing inflammation in organoids from UC patients
Role of immune cells in intestinal fibrosis
Association between meat consumption and IBD risk
CD exclusion diet corrects dysbiosis
Related Articles
April 14, 2020
Phase 2 results of first-in-class TL1A inhibitor
April 14, 2020
The positive impact of genetic data on drug development
April 14, 2020
Response to faecal microbiota transplantation in UC
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com